Seres Therapeutics Stock News

Seres Therapeutics, Inc. (NASDAQ:MCRB)s stock price fell 2.5% during mid-day trading on Thursday . The stock traded as low as $8.41 and last traded at $8.51. 2,457 shares changed hands during trading, a decline of 100% from the average session volume of 1,435,048 shares. The stock had previously closed at $8.73. Separately, Zacks Investment Research []

Equities analysts forecast that Seres Therapeutics, Inc. (NASDAQ:MCRB) will report ($0.45) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Seres Therapeutics earnings, with estimates ranging from ($0.62) to ($0.03). Seres Therapeutics posted earnings per share of ($0.18) during the same quarter last year, which would []

This is the 3rd hour in a row mcrb has seen its price head up. The post Seres Therapeutics Inc (MCRB): Price Now Near $10.78; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .

In the last trading session, 2.51 million Seres Therapeutics Inc. (NASDAQ:MCRB) shares changed hands as the company’s beta touched 3.52. With the company’s per share price at $10.68 changed hands at -$0.75 or -6.56% during last session, the market valuation stood at $1.05B. MCRB’s last price was a discount, traded about -179.96% off its 52-week … Seres Therapeutics Inc. (NASDAQ: MCRB) Is The Most Intriguing Stock Today. Read More »

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Seres Therapeutics, Inc. (NASDAQ: MCRB) is "too speculative" for an older person, as the company is not making any money. However, he recommen

Bank of America Corp DE reduced its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 1.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 149,266 shares of the biotechnology companys stock after selling 2,737 shares during the quarter. Bank of []

The post I prefer Pfizers stock over Novavax appeared on BitcoinEthereumNews.com . Seres Therapeutics: Youre a younger person and youre new and I think you can buy it. For an older person, its too speculative because the company is not making any

The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) increased by over 20% during intraday trading today. This is why it happened.

Wall Street brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report earnings per share of ($0.53) for the current quarter, according to Zacks. Four analysts have issued estimates for Seres Therapeutics earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.62). Seres Therapeutics reported earnings per share of []

Brokerages forecast that Seres Therapeutics, Inc. (NASDAQ:MCRB) will post $6.41 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Seres Therapeutics earnings, with estimates ranging from $5.00 million to $9.64 million. Seres Therapeutics posted sales of $17.56 million during the same quarter last year, which []

Wall Street brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to post $6.41 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Seres Therapeutics earnings, with estimates ranging from $5.00 million to $9.64 million. Seres Therapeutics posted sales of $17.56 million in the same quarter last year, which []